{"id":218222,"date":"2025-07-18T09:08:12","date_gmt":"2025-07-18T14:08:12","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/07\/guselkumab-demonstrates-superior-efficacy-in-clinical-trials-offering-new-hope-to-crohns-disease-patients"},"modified":"2025-07-18T09:08:12","modified_gmt":"2025-07-18T14:08:12","slug":"guselkumab-demonstrates-superior-efficacy-in-clinical-trials-offering-new-hope-to-crohns-disease-patients","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/07\/guselkumab-demonstrates-superior-efficacy-in-clinical-trials-offering-new-hope-to-crohns-disease-patients","title":{"rendered":"Guselkumab demonstrates superior efficacy in clinical trials, offering new hope to Crohn\u2019s disease patients"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/guselkumab-demonstrates-superior-efficacy-in-clinical-trials-offering-new-hope-to-crohns-disease-patients.jpg\"><\/a><\/p>\n<p>In a major advance for patients with Crohn\u2019s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief.<\/p>\n<p>These findings from two pivotal Phase III <a href=\"https:\/\/medicalxpress.com\/tags\/trials\/\" rel=\"tag\" class=\"\">trials<\/a> known as GALAXI 2 and 3, <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(25)00681-6\/fulltext\" target=\"_blank\">published<\/a> in <i>The Lancet<\/i>, provided the basis for the recent Food and Drug Administration approval of guselkumab (brand name Tremfya) for the treatment of moderately to severely active Crohn\u2019s disease.<\/p>\n<p>Crohn\u2019s disease affects roughly 780,000 people in the United States and often requires a lifetime of management. Despite numerous available biologic medications, many patients fail to achieve sustained remission. Guselkumab blocks the interleukin-23 (IL-23) pathway, a key driver of chronic intestinal inflammation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a major advance for patients with Crohn\u2019s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief. These findings from [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-218222","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/218222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=218222"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/218222\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=218222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=218222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=218222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}